Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Site Management--A New Name in Contract Research

This article was originally published in Start Up

Executive Summary

During the last five years private practice physicians have taken a bite out of academia’s traditionally dominant role in clinical research. The site management organization is the next step in the professionalization of clinical research. Site management organizations are embarking on a venture, equity-backed horizontal expansion. Will the consolidation of clinical researchers lead to vertical integration of CRO services?

You may also be interested in...



The People Business: The Renaissance of Population Genetics

New technologies enable the rapid processing of genetic information, but since gene data isn't associated with specific diseases and diseased tissues, in and of itself it isn't clinically useful. A new breed of start-ups aims to provide both the phenotypic and genotypic sides of the equation by creating databases of patients and patient samples. Still unclear is how much drug firms will pay for disease-associated gene data; genetics firms are taking various approaches to monetizing their databases, from focusing initially on high-value diagnostics to creating true target-discovery businesses, to selling their data along with associated software and services. There are also ethical issues to hammer out. The new companies must take care to protect patients' rights. They must consider the need for explicit consent to use the information collected from patients, especially when they are participating in research whose purpose is as yet undefined.

Re-Engineering Drug Development II: Clinical Data Collection & Management

Despite a history of failed products, start-up companies are looking to reinvent how data from clinical trials is collected and managed. Firms are trying to replace the point solutions of the past with broad software offerings that can take clients from "site to submission."

Re-Engineering Drug Development I: Simulating Clinical Trials

As the cost and complexity of clinical drug development increases, start-ups are creating new technologies to speed things along. In Part I of our survey, we look at companies adapting computer simulation techniques from industries like aerospace to develop and design clinical trials. The two top simulation companies are thrashing out strategies as they debate adopting product or service business models.

Topics

Related Companies

UsernamePublicRestriction

Register

SC089708

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel